CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
EUROPE
APAC
CANADA
  • US
    • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Home
  • Contributors
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • Magazine
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • News

Recommended picks

Myriad Genetics And Epic Join Forces To Expand Access To Genetic Testing For More Patients

Myriad Genetics And Epic Join Forces...

Masco Group now a major stakeholder of Swedish company, KeyPlants AB

Masco Group now a major stakeholder...

The Value of New Antibiotics in the Fight Against AMR

The Value of New Antibiotics in the...

Improving Minimal Residual Disease Detection Using NGS

Improving Minimal Residual Disease...

Multiomic Preclinical Models to Define the Mechanism of Action

Multiomic Preclinical Models to...

Developing Patient-Centric Precision Oncology Therapies: Begin With The End In Mind

Developing Patient-Centric Precision...

What the New EMA Draft

What the New EMA Draft "Guideline on...

Pharmaceutical Tablet Coating - Past, Present and Future

Pharmaceutical Tablet Coating - Past,...

Myriad Genetics And Epic Join Forces To Expand Access To Genetic Testing For More Patients

Myriad Genetics And Epic Join Forces...

Masco Group now a major stakeholder of Swedish company, KeyPlants AB

Masco Group now a major stakeholder...

The Value of New Antibiotics in the Fight Against AMR

The Value of New Antibiotics in the...

Improving Minimal Residual Disease Detection Using NGS

Improving Minimal Residual Disease...

Multiomic Preclinical Models to Define the Mechanism of Action

Multiomic Preclinical Models to...

Developing Patient-Centric Precision Oncology Therapies: Begin With The End In Mind

Developing Patient-Centric Precision...

What the New EMA Draft

What the New EMA Draft "Guideline on...

Pharmaceutical Tablet Coating - Past, Present and Future

Pharmaceutical Tablet Coating - Past,...

How AIin Biotech and PharmaceuticalImpacts Drug Discovery

Life Sciences Review | Tuesday, March 30, 2021
Tweet

Artificial Intelligence is being used in Biotech and pharmaceuticals during drug discovery as it can increase the speed and accuracy of the process. 


FREMONT, CA : AI could help reduce expense, operationalize processes, assist in scale, and decrease errors in data-intensive industries with a lot at stake. The method of drug discovery is a prime example of this. AI in Biotech and pharmaceuticals can help since drug discovery is a slow process, but it can be expensive. It's time-consuming and costly, with just 10 percent of drugs making it through clinical trials.


AI allows faster drug development through more robust, more reliable data processing and prediction capabilities, but companies would remiss if they only concentrate on this narrow field of Biotech. Artificial intelligence (AI) can be applied to almost every aspect of pharmaceuticals, making it a much more exciting and valuable product than anyone previously believed.


Here are some things companies must be paying attention to in the Ai-Biotech mashup


Personalized Medicine


Drug discovery is one thing, but biotech companies hope to use AI in the next few years to have more personalized medicine. The customized treatment has the ability to reduce side effects and adverse outcomes, resulting in improved patient treatments and fewer recalls or litigation.


 


 


For the time being, deep generative models generate realistic samples from training data, circumventing around medical data silos. It may be critical for filling in information gaps in a sector with high privacy walls and deeply rooted segmentation.


Diagnostics


Biotech companies are planning to use AI's data processing to detect possible diseases faster and more accurately. AI's precision in identifying disease states was one percentage point higher than that of medical practitioners in early trials and two percentage points higher in accuracy in all-clear declarations.


AI appears to be highly promising in relieving the burden on overworked medical professionals, especially in areas where medical care is limited. AI's data processing ability stands out as doctors are given less time with patients, and patients are less likely to (or unable to) receive routine treatment.


See Also :- Top Artificial Intelligence Solution Companies


Weekly Brief

loading
> <
  • Regulatory Services 2023

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue
  • Regulatory Services 2023

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue

Read Also

The Role of AI in Accurate Medical Writing

Patrik Renblad to Join Cantargia as Chief Financial Officer

Overview of the Life Sciences BPO Market

Dr. Zamaneh Mikhak Joins TFF Pharmaceutical as the New Chief Medical Officer

The Significance of AI in Medical Writing

The Importance of Technology in Multinational Clinical Research

Hepion Pharmaceuticals to Get a Total of $ 3.2 Million in Non-Dilutive Financing

Benefits that Medical Writing Offers

Loading...

Copyright © 2023 Life Sciences Review . All rights reserved. |  Subscribe |  About Us follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/news/how-aiin-biotech-and-pharmaceuticalimpacts-drug-discovery--nwid-306.html